Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24619322 | 1.00 | HTR2A (0.43) | HTR2AKDM1ARENAAK1DPP4 | |
| SCHEMBL24619325 | 0.84 | HTR2A (0.42) | HTR2ARENDPP4HSD11B1 | |
| SCHEMBL29925353 | 0.82 | KDM1A (0.43) | HTR2AKDM1ACETPHDAC8HDAC6 | |
| SCHEMBL24619382 | 0.82 | KDM1A (0.43) | HTR2AKDM1ACETPHDAC8HDAC6 | |
| SCHEMBL12584034 | 0.79 | REN (0.36) | HTR2AKDM1ARENCETPHDAC8 | |
| SCHEMBL22899905 | 0.77 | NR1H4 (0.37) | HTR2AKDM1ARENCETPHDAC8 | |
| SCHEMBL22254800 | 0.77 | REN (0.45) | HTR2AKDM1ARENAAK1 | |
| SCHEMBL30401123 | 0.77 | REN (0.45) | HTR2AKDM1ARENAAK1 | |
| SCHEMBL663586 | 0.76 | REN (0.43) | RENAAK1HSD11B1 | |
| SCHEMBL1074688 | 0.75 | HDAC8 (0.41) | HTR2AKDM1ARENCETPHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274569-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | HTR2A 4149/4885KDM1A 3210/4885REN 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.